Clinical depression, diagnosed in 5-15% of women during pregnancy, increases the risk of negative pregnancy outcomes including an increased incidence of low birth weight newborns and preterm delivery. Fluoxetine, a selective serotonin reuptake inhibitor, is often prescribed to treat depression due to its efficacy, high margin of safety, and mild side effects. However, fluoxetine initially increases plasma serotonin concentration, and serotonin causes uterine vasoconstriction in sheep, which could result in fetal hypoxemia. To assess fetal fluoxetine effects, late-gestation pregnant sheep were surgically prepared for the measurement of blood gases, heart rate, blood pressure, and uterine artery blood flow (n ϭ 29). Ewes received a 70-mg bolus i.v. infusion of fluoxetine over 2 min in 10 mL of sterile water followed by continuous infusion at a rate of 100 g/min for 8 d (n ϭ 14), or continuous infusion of sterile water (n ϭ 15). Transient decreases in uterine artery blood flow, fetal PO 2 , and oxygen saturation were observed within the first 15 min after fluoxetine exposure, which did not return to normal values by 24 h. Fetal pH decreased and PCO 2 increased over the first 4 h with a return to normal by 24 h. However, there were no differences in uterine artery blood flow, blood gas status, or cardiovascular measures between the control and fluoxetine group over the rest of the 8-d infusion period. Thus, fluoxetine exposure during pregnancy has transient effects on fetal status that may be of developmental consequence if they occur repetitively. Depression occurs in 5-15% of pregnant women, and an additional 10 -15% of women experience postpartum depression (1). A study of general practitioner records in the United Kingdom from 1991 to 1996 showed that FX is the most prescribed SSRI (2). The SSRIs have fewer side effects than tricyclic antidepressants and monoamine oxidase inhibitors and thus are frequently prescribed during pregnancy (3). First trimester in utero exposure to FX does not result in teratogenic effects in humans (4, 5), whereas third trimester exposure has been reported to increase the incidence of preterm delivery, admission to special care nursery, poor neonatal adaptation, and to decrease birth weight (6, 7). However, other studies have found no difference in birth weight, perinatal complications, or neurobehavioral development (8, 9).Chronic FX treatment enhances serotonin neurotransmission by inhibiting serotonin reuptake by the serotonin transporter. In addition, presynaptic inhibitory 5HT 1A and 5HT 1D/1B receptors are desensitized (9). Serotonin causes contraction of the human and sheep umbilical artery (10, 11). Injections of serotonin into the uterine artery in pregnant and nonpregnant sheep results in dose-dependent decreases in UABF ranging from 20% to 50% at doses of 1-10 g (12). Whether FX interacts directly with serotonin receptors or through changes in plasma levels of serotonin, a decrease in UABF, either chronic or repeated, may be a mechanism for the possible negative effects of ...